Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Net Cash Flow: 2012-2025

Historic Net Cash Flow for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $11.8 million.

  • Agios Pharmaceuticals' Net Cash Flow fell 93.00% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.0 million, marking a year-over-year decrease of 185.02%. This contributed to the annual value of -$12.0 million for FY2024, which is 76.58% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Net Cash Flow stood at $11.8 million, which was up 520.82% from $1.9 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Net Cash Flow high stood at $1.8 billion for Q1 2021, and its period low was -$918.9 million during Q2 2021.
  • In the last 3 years, Agios Pharmaceuticals' Net Cash Flow had a median value of $1.9 million in 2025 and averaged -$4.2 million.
  • Data for Agios Pharmaceuticals' Net Cash Flow shows a peak YoY increase of 20,807.13% (in 2021) and a maximum YoY decrease of 955.61% (in 2021) over the last 5 years.
  • Over the past 5 years, Agios Pharmaceuticals' Net Cash Flow (Quarterly) stood at -$197.1 million in 2021, then soared by 108.53% to $16.8 million in 2022, then surged by 42.01% to $23.9 million in 2023, then slumped by 843.48% to -$177.5 million in 2024, then crashed by 93.00% to $11.8 million in 2025.
  • Its Net Cash Flow stands at $11.8 million for Q3 2025, versus $1.9 million for Q2 2025 and $2.7 million for Q1 2025.